Secura Bio, Inc.
10
2
4
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
30.0%
3 terminated/withdrawn out of 10 trials
50.0%
-36.5% vs industry average
0%
0 trials in Phase 3/4
133%
4 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
Role: collaborator
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
Role: collaborator
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
Role: collaborator
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
Role: collaborator
Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma
Role: collaborator
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
Role: collaborator
Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
Role: collaborator
A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT
Role: collaborator
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study
Role: collaborator
Phase I Study of Marizomib + Panobinostat for Children With DIPG
Role: collaborator
All 10 trials loaded